Posts

Surgical outcomes of perioperative durvalumab in AEGEAN...

[Singapore, 10:05 a.m. SGT–September 11, 2023] – Adding perioperative durvalumab...

Asensus and Nvidia collaborate on digital surgical AI

Asensus Surgical, a player in the surgical commercial sector, is embarking on a ...

Trialbee’s new tool aims to expedite clinical trial rec...

Clinical trials play a pivotal role in advancing medical research and the develo...

Digital dilemma in UK’s life sciences job market

In this issue: Digital jobs in UK life sciences, generative AI changes drug disc...

Hope for the UK clinical trial landscape but it require...

The Arena International Outsourcing in Clinical Trials UK and Ireland discussed ...

FDA fast tracks Mendus’s acute myeloid leukaemia vaccin...

The company expects a further survival readout in Q4 2023, with plans for a seco...

Eloxx moves ahead with plans with gene therapy for rare...

Eloxx has submitted an IND for a pivotal trial to study its Alport syndrome ther...

Record number of respiratory syncytial virus (RSV) desi...

In 2022, global regulatory authorities awarded a record ten review designations ...

Otsuka and ShapeTX to develop gene therapies for eye di...

Otsuka Pharmaceutical has entered a partnership with ShapeTX for the development...

NICE recommends Lilly’s tirzepatide to treat T2D

The UK NICE has recommended Eli Lilly’s tirzepatide for the treatment of adult p...

EC expands indication approval for Merck’s Ebola vaccine

The European Commission granted expanded indication approval for Merck’s Ebola v...

Biocytogen and Myricx Bio partner for development of ADCs

Biocytogen and Myricx Bio have signed an antibody evaluation, option and licence...

Subcutaneous drugs grant a new lease on life to checkpo...

The PD-1/PD-L1 inhibitor landscape is at the precipice of change with the approv...

ALS advocates say criticism of new drugs misses bigger ...

Brian Wallach, ALS advocate: “We know that these treatments are not cures, but t...

How a supplement company became a haven for health misi...

“The idea that these supplements would be marketed in a way that people have a h...

STAT+: Why Novartis is changing the name of its researc...

Swiss drugmaker Novartis’ research and development hub has a new name — and a ne...